SARMS

Hemi Pharma SARMs

Hemi Pharma produces six SARMs in capsule form, available exclusively through hemipharmauk.uk. The range covers the most widely researched selective androgen receptor modulators alongside two compounds that are frequently grouped with SARMs but operate through entirely different mechanisms: MK-677 (a growth hormone secretagogue) and Cardarine (a PPARdelta agonist). Selective androgen receptor modulators are designed to bind to androgen receptors in a tissue-selective manner. Unlike anabolic steroids, which bind to androgen receptors throughout the body and produce systemic androgenic effects including prostate stimulation, hair follicle miniaturisation and suppression of the HPTA, SARMs are intended to activate androgen receptors selectively in muscle and bone tissue with reduced activity in other tissues. The degree to which this selectivity holds in practice varies by compound and dose, which is why the suppression profiles of individual SARMs differ significantly from one another. Hemi Pharma SARMs are produced in capsule form. Capsule form provides consistent and measurable per-dose accuracy. Liquid SARMs, by contrast, require careful measurement of a solution that may not be homogenously mixed, introducing variability in the dose drawn per administration. Every Hemi Pharma SARM is independently batch-tested before reaching the UK market and is QR-verified on every unit.

Understanding the Hemi Pharma SARMs Range

Ostarine (MK-2866) is the most studied SARM in the range and is considered to have one of the milder suppression profiles at research doses. It binds to androgen receptors with high affinity and is primarily associated with lean muscle preservation and joint support. It is commonly used as a first SARM, in female protocols and during cutting phases where muscle retention alongside calorie restriction is the primary objective. RAD-140 (Testolone) is more potent than Ostarine and produces a stronger anabolic signal at lower doses. It has a high anabolic to androgenic ratio and does not convert to oestrogen. Suppression is more pronounced than Ostarine at standard doses, making post cycle therapy more commonly recommended after a full RAD-140 cycle. LGD-4033 (Ligandrol) produces significant anabolic effects with moderate suppression. It is one of the most frequently researched SARMs for lean mass accrual. At doses above 5mg per day, suppression becomes more meaningful and a SERM-based post cycle therapy is generally recommended. YK-11 is distinct from the other compounds in this range. It is a myostatin inhibitor as well as a partial androgen receptor agonist. Myostatin is a protein that limits muscle growth. By inhibiting myostatin, YK-11 removes this ceiling on muscle development through a mechanism that the other SARMs in this range do not replicate. It is considered one of the more potent compounds in the range and carries a corresponding suppression profile. MK-677 (Ibutamoren) is not a SARM. It is a growth hormone secretagogue that stimulates the pituitary to release growth hormone by mimicking the action of ghrelin. It does not bind to androgen receptors and does not suppress natural testosterone production. This makes it one of the only compounds in this range that does not require post cycle therapy. It is frequently stacked with true SARMs because it adds a growth hormone stimulus without contributing to androgenic suppression. Cardarine (GW-501516) is also not a true SARM. It is a PPARdelta receptor agonist. It does not bind to androgen receptors. Its primary association is with endurance, fat oxidation and metabolic adaptation. It does not cause androgenic suppression and does not require post cycle therapy. It is included in this range because it is routinely used alongside SARM protocols for its complementary metabolic effects.

Do Hemi Pharma SARMs Require Post Cycle Therapy?

Whether post cycle therapy is required after a Hemi Pharma SARM cycle depends on the specific compound, the dose and the duration of use. MK-677 and Cardarine do not suppress natural testosterone production and do not require PCT. Ostarine at low doses and short durations causes mild suppression that some users manage without formal PCT. RAD-140, LGD-4033 and YK-11 at standard doses and full cycle lengths cause meaningful suppression and a SERM-based PCT protocol is generally recommended. The Hemi Pharma PCT range includes Tamoxifen (Tamox) and Clomiphene Citrate as the primary SERM options for recovery after a suppressive SARM cycle.

What You Will Need Alongside SARMs

Some users run Hemi Pharma SARMs alongside a low-dose testosterone base from the Hemi Pharma injectable steroid range to maintain physiological testosterone levels during suppressive SARM cycles. MK-677 is commonly stacked with other SARMs in this range because it adds growth hormone stimulation without contributing to androgenic suppression. BPC-157 and TB-500 from the Hemi Pharma peptides range are used alongside SARMs for connective tissue and recovery support. Post cycle therapy for suppressive SARMs is available in the Hemi Pharma PCT range.

Hemi Pharma SARMs Frequently Asked Questions

What SARMs does Hemi Pharma produce?

Hemi Pharma produces six compounds in the SARMs range: Ostarine (MK-2866) at £33.99, RAD-140 at £38.99, LGD-4033 at £40.00, YK-11 at £40.00, MK-677 at £35.00 and Cardarine (GW-501516) at £35.00. All are produced in capsule form and independently tested before reaching the UK market.

What is the difference between Ostarine and RAD-140?

Ostarine (MK-2866) is milder with a lower suppression profile, making it suitable for first SARM cycles, female protocols and cutting phases. RAD-140 (Testolone) is more potent with a stronger anabolic signal and more pronounced suppression at standard doses. RAD-140 produces greater muscle-building stimulus but requires more careful management of suppression and is more commonly followed by a formal PCT protocol. Is MK-677 a SARM? No. MK-677 (Ibutamoren) is a growth hormone secretagogue that stimulates pituitary release of growth hormone by mimicking ghrelin. It does not bind to androgen receptors and does not suppress natural testosterone production. It does not require post cycle therapy. It is included in the Hemi Pharma SARMs range because it is commonly used alongside true SARMs to add a growth hormone stimulus without contributing to androgenic suppression.

Is Cardarine a SARM?

No. Cardarine (GW-501516) is a PPARdelta receptor agonist. It does not bind to androgen receptors and does not suppress natural testosterone production. It is associated with endurance, fat oxidation and metabolic adaptation. It does not require post cycle therapy.

What is YK-11 and how does it differ from other SARMs?

YK-11 is a myostatin inhibitor as well as a partial androgen receptor agonist. Myostatin is a protein that limits muscle growth, and YK-11 inhibits it, removing a ceiling on muscle development that the other SARMs in the range do not address. It is considered one of the more potent compounds in the Hemi Pharma SARMs range with a corresponding suppression profile requiring post cycle therapy.

Do Hemi Pharma SARMs require post cycle therapy?

It depends on the compound. MK-677 and Cardarine do not suppress testosterone and do not require PCT. Ostarine at low doses causes mild suppression. RAD-140, LGD-4033 and YK-11 at standard doses cause meaningful suppression and a SERM-based PCT protocol is generally recommended. Tamoxifen and Clomiphene Citrate from the Hemi Pharma PCT range are the standard SERM options after a suppressive SARM cycle. Why does Hemi Pharma produce SARMs in capsule form rather than liquid? Capsule form provides consistent per-dose accuracy. Liquid SARMs require measurement of a solution that may not be evenly mixed throughout, introducing dose variability. Capsules deliver the same amount of active compound in every unit without the measurement uncertainty associated with liquid administration.

Can Hemi Pharma SARMs be stacked together?

Yes. Common stacks include Ostarine with Cardarine for a cutting protocol, LGD-4033 with MK-677 for lean mass accrual without additional androgenic suppression from the MK-677, and RAD-140 with Cardarine for a combination of anabolic stimulus and endurance support. Stacking suppressive SARMs together increases the combined suppression load and the importance of appropriate post cycle therapy.